Skip to main content
Signal8

Liminatus Pharma, Inc. (LIMN) Form 8-K — Nov 3, 2026

$LIMNForm 8-KItems 1.01, 3.02, 9.01Filed Nov 3, 2026, 4:15 PM ET0001104659-26-122012Original filing

Liminatus Pharma entered into a subscription agreement on November 2, 2026 with a non-U.S. investor to sell 260,001 shares of common stock at $2.50 per share in a private placement, for aggregate gross proceeds of $650,002.50. Proceeds are earmarked for working capital and general corporate purposes. The offering is exempt from registration under Section 4(a)(2), Regulation D and/or Regulation S, and is expected to close on or about November 20, 2026.

Key figures

Gross Proceeds
650002.5
Offering Price
2.5
Shares Offered
260001
Closing Date
on or about November 20, 2026
Outside Date
December 31, 2026
Resale Registration Deadline
within 60 days of closing

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.